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Abstract
Aims Liver dysfunction is important for prognosis in heart failure (HF). Shear wave elastography (SWE), which is a novel ul-
trasound technique for charactering tissues, has been used in liver diseases. However, clinical implication of SWE, including
dispersion slope, remains unknown in heart diseases. This study aimed to evaluate the efficacy of SWE assessing liver function
in the severity of HF.
Methods and results We enrolled 316 consecutive patients with or suspected heart diseases, who were classified according
to the American College of Cardiology Foundation/American Heart Association stage of HF, including 37 with Stage A, 139 with
Stage B, 114 with Stage C, and 26 with Stage D, and 45 normal subjects. Elasticity and dispersion slope of shear wave were
assessed according to the HF stage. Elasticity and dispersion slope were not elevated in normal subjects and patients with
Stage A. Elasticity was slightly increased from Stage A to Stage C and was remarkably elevated in Stage D (normal:
5.2 ± 1.1 kPa, Stage A: 5.4 ± 1.2 kPa, Stage B: 6.4 ± 1.8 kPa, Stage C: 7.8 ± 3.5 kPa, and Stage D: 17.7 ± 12.7 kPa), whereas
dispersion slope was gradually increased from Stage A to Stage D (normal: 9.7 ± 1.7m/s/kHz, Stage A: 10.4 ± 1.6m/s/kHz, Stage
B: 11.7 ± 2.4m/s/kHz, Stage C: 13.2 ± 3.4m/s/kHz, and Stage D: 17.6 ± 5.6 m/s/kHz). In the early HF stage, dispersion slope was
elevated. In the advanced HF stage, both elasticity and dispersion slope were elevated. Liver function test abnormalities were
observed only from Stage C or Stage D.
Conclusions Dispersion slope could detect early liver damage, and the combination of elasticity and dispersion slope could
clarify the progression of liver dysfunction in HF. SWE may be valuable to manage therapeutic strategies in patients with HF.
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Introduction
Heart failure (HF) is a clinical syndrome that leads to multiple
organ injuries, including liver dysfunction. Cardiohepatic in-
teraction has been reported to associate with a poor progno-
sis in patients with HF.1–3 Passive hepatic congestion due to
increased central venous pressure causes liver dysfunction,
which presents as an abnormality called nutmeg liver on
pathological examination.4–6 The management of HF in the
early stage, prior to the progression of liver dysfunction, is
important to improve clinical outcomes.
Shear wave elastography (SWE) is a novel ultrasound tech-
nique that is used to assess tissue characteristics based on
shear wave propagation velocity, which provides quantitative
estimates of tissue elasticity and viscosity.7–10 Shear wave is
generated by inducing a push pulse of ultrasound wave,
which deforms a part of the tissue. The velocity of shear
wave within the tissue is detected by tracking pulse. SWE
can be used to measure two parameters such as elasticity
of shear wave, which is related to the tissue hardness, and
dispersion slope of shear wave, which reflects the tissue
viscosity.11,12
Shear wave elastography has been used to evaluate liver
diseases, including fatty liver, hepatitis, and cirrhosis. Elastic-
ity is correlated with the degree of fibrosis.13,14 Dispersion
slope is associated with inflammation, necrosis, and
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steatosis.15–17 A few recent studies in the field of heart dis-
eases have reported that elasticity measured on the liver is
related to adverse outcomes in patients with HF.18 However,
the clinical implication of SWE has not been well investigated
in patients with HF. Especially, the clinical significance of dis-
persion slope remains unknown.
Hepatic congestion results in compression of the bile can-
aliculi and ductules, causing necrosis of liver cells. Persistence
of HF extends the liver cells necrosis, contributing to liver
fibrosis.19 Therefore, we hypothesized that dispersion slope,
which reflects the viscosity, is sensitively elevated in the early
stage of HF to reflect hepatic congestion and that the combi-
nation of elasticity and dispersion slope is useful to clarify the
progression of liver dysfunction in patients with HF. The aim
of this study was to evaluate the efficacy of SWE for assess-




We prospectively enrolled 316 consecutive patients with con-
firmed or suspected heart diseases and 45 normal subjects
who underwent SWE in Okayama University Hospital from
March 2018 to May 2020. Patients were classified according
to the American College of Cardiology Foundation/American
Heart Association stage of HF.20 The stage of HF was
diagnosed based on medical history, symptoms, physical
examinations, and clinical examinations, including electrocar-
diogram, echocardiography, biomarker measurements, and
chest X-ray. Normal subjects were defined as those with no
history of heart diseases and no abnormal findings on clinical
examinations. Patients with a history or signs of liver diseases
such as fatty liver, hepatitis, cirrhosis, and/or hepatic tumours
and a history of alcohol abuse (≥20 g/day) were excluded. Pa-
tients undergoing dialysis and those with congenital heart
diseases were also excluded. All patients gave informed con-
sent to undergo examination. The study was approved by the
ethical committee of our institution.
Shear wave elastography
Shear wave elastography measurements for assessment of
liver function were performed using Aplio i900 with a 3.5 to
5.0 MHz convex probe (Canon Medical Systems, Otawara,
Japan) at the time of outpatient clinic or at discharge from
HF treatment. SWE was obtained on the right lobe of the liver
through the intercostal spaces at the end-expiratory period in
the supine position. Patients were requested to hold their
breath during the acquisition. The grey-scale image was opti-
mized for the best acoustic window and best gain setting. A
sample box of 2.0 × 2.0 cm was placed on the grey-scale im-
age at a depth of 1.0 to 1.5 cm from the liver capsule to
avoid reverberation artefacts and intrahepatic vessels. A
Figure 1 Shear wave elastography. Shear wave elastography was performed on the right lobe of the liver through intercostal spaces. A sample box of
2.0 × 2.0 cm was placed. A 1.0-cm-diameter circular region of interest was placed on the propagation map.
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1.0-cm-diameter circular region of interest was placed on the
propagation map and exhibited smooth and parallel lines
(Figure 1).11,21 SWE measurements were performed 10 times
in each patient, and the average elasticity and dispersion
slope of shear wave were calculated.
Clinical assessments
Transthoracic echocardiography was performed at the same
time as the SWE measurements. Left ventricular (LV)
end-diastolic diameter, LV end-systolic diameter, LV ejection
fraction, LV mass index, left atrial volume index, early dia-
stolic mitral inflow velocity to mitral annular velocity ratio
(E/e′), tricuspid regurgitation pressure gradient, and inferior
vena cava diameter were measured. Furthermore, we evalu-
ated right atrial (RA) size by measuring RA area in the apical
four-chamber view. Liver function tests were also performed,
including measurement of aspartate aminotransferase (AST),
alanine aminotransferase (ALT), alkaline phosphatase (ALP),
γ-glutamyl transpeptidase (GGT), bilirubin, cholinesterase, al-
bumin, and prothrombin time levels. Haemoglobin, plasma
B-type natriuretic peptide, and serum creatinine levels were
also measured.
Cardiac catheterization was performed in 94 of the 316 pa-
tients, based on the judgement of physicians. Pulmonary ar-
tery wedge pressure, mean pulmonary artery pressure,
systolic right ventricular pressure, RA pressure, cardiac out-
put, and cardiac index were obtained. The measurements
were determined at the end-expiratory period, with an aver-
age of five cycles. Cardiac output and cardiac index were cal-
culated using the Fick equation.
Variability
Inter-observer and intra-observer differences were analysed
in 20 randomly selected images. SWE was evaluated by two
blinded observers and by a single observer at two different
times. Reliability was calculated using Pearson’s correlation
coefficient. Variability was calculated as the percentage error
of each measurement and derived as the difference between
the measurements divided by the mean value.
Statistical analysis
Data are presented as mean ± standard deviation for contin-
uous variables and as number and percentage for categorical
variables. The analysis of variance or the Wilcoxon rank-sum
test was used to explore differences for continuous variables
between the groups. The χ2 test was used to compare for cat-
egorical variables. The cut-off values of elasticity and disper-
sion slope for the HF stage were estimated using receiver
operating characteristic curve. Pearson’s correlation
coefficient was calculated to identify the relationship be-
tween SWE and clinical parameters. Statistical analysis was
performed with statistical software (JMP Version 14.0; SAS
Institute Inc., Cary, NC, USA), and significance was defined
as a P value of <0.05.
Results
Clinical characteristics
The study population consisted of 316 patients, including 37
with Stage A, 139 with Stage B, 114 with Stage C, and 26 with
Stage D, and 45 normal subjects. The mean age of all patients
was 66 ± 16 years. Comparisons of clinical characteristics be-
tween the groups are shown in Table 1. As the HF stage ad-
vanced, age was increased, and body mass index was
decreased. The prevalence of hypertension and dyslipidaemia
was higher in Stages A–C. Atrial fibrillation was observed
more frequently in Stage D. LV end-diastolic diameter and
LV end-systolic diameter were increased, and LV ejection
fraction was decreased in Stages C and D. E/e′ ratio and left
atrial volume index were increased in Stages B–D. Tricuspid
regurgitation pressure gradient and inferior vena cava diam-
eter were higher in Stage D.
Shear wave elastography
The values of SWE for each group were shown in Figure 2.
Elasticity of shear wave was 5.2 ± 1.1 kPa in normal subjects,
5.4 ± 1.2 kPa in patients with Stage A, 6.4 ± 1.8 kPa in patients
with Stage B, 7.8 ± 3.5 kPa in patients with Stage C, and
17.7 ± 12.7 kPa in patients with Stage D. Dispersion slope
of shear wave was 9.7 ± 1.7 m/s/kHz in normal subjects,
10.4 ± 1.6 m/s/kHz in patients with Stage A, 11.7 ± 2.4 m/s/
kHz in patients with Stage B, 13.2 ± 3.4 m/s/kHz in patients
with Stage C, and 17.6 ± 5.2 m/s/kHz in patients with Stage
D. Elasticity and dispersion slope were not elevated in normal
subjects or those with Stage A. Elasticity was slightly in-
creased from Stage A to Stage C and was remarkably elevated
in Stage D. Dispersion slope was gradually increased from
Stage A to Stage D. In the early stage of HF, dispersion slope
was elevated. In the advanced stage of HF, both elasticity and
dispersion slope were increased. The cut-off value of disper-
sion slope between Stages A and B was 11.5 m/s/kHz, with
area under the curve of 0.68, sensitivity of 56%, and specific-
ity of 79%, and the cut-off value between Stages B and C was
12.9 m/s/kHz, with area under the curve of 0.62, sensitivity of
50%, and specificity of 76%. The cut-off value of elasticity be-
tween Stages C and D was 14.6 kPa, with area under the
curve of 0.79, sensitivity of 50%, and specificity of 95%.
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Table 1 Clinical characteristics
Variables
Normal Stage A Stage B Stage C Stage D
P(n = 45) (n = 37) (n = 139) (n = 114) (n = 26)
Age (years) 51 ± 17 64 ± 13 66 ± 16 71 ± 11 71 ± 9 <0.01
Male 18 (40%) 18 (49%) 74 (53%) 53 (47%) 16 (62%) 0.37
Body mass index (kg/m2) 22.4 ± 3.4 22.8 ± 4.0 22.6 ± 3.5 22.7 ± 4.1 19.8 ± 2.6 <0.01
Hypertension 0 (0%) 24 (65%) 62 (45%) 47 (41%) 5 (19%) <0.01
Dyslipidaemia 0 (0%) 23 (62%) 62 (45%) 52 (46%) 8 (31%) <0.01
Diabetes mellitus 0 (0%) 11 (30%) 32 (23%) 32 (28%) 8 (31%) <0.01
Atrial fibrillation 0 (0%) 0 (0%) 22 (19%) 18 (20%) 10 (38%) <0.01
Heart diseases
Ischaemic heart disease 0 (0%) 0 (0%) 40 (29%) 15 (13%) 5 (19%) <0.01
Cardiomyopathy 0 (0%) 0 (0%) 25 (18%) 71 (62%) 13 (50%) <0.01
Valvular disease 0 (0%) 0 (0%) 16 (12%) 21 (18%) 4 (15%) <0.01
Echocardiography
LV end-diastolic diameter (mm) 44 ± 3 44 ± 4 46 ± 6 53 ± 10 58 ± 10 <0.01
LV end-systolic diameter (mm) 28 ± 2 28 ± 4 31 ± 8 42 ± 12 46 ± 15 <0.01
LV ejection fraction (%) 64 ± 4 64 ± 5 60 ± 11 43 ± 17 40 ± 13 <0.01
LV mass index (g/m2) 70 ± 13 73 ± 15 94 ± 27 122 ± 35 131 ± 48 <0.01
E/e′ ratio 8.1 ± 2.1 9.6 ± 2.9 12.6 ± 6.5 17.3 ± 8.2 28.4 ± 13.1 <0.01
Left atrial volume index (mL/m2) 28 ± 5 29 ± 7 42 ± 23 56 ± 25 90 ± 53 <0.01
RA size (cm2) 12 ± 2 13 ± 3 17 ± 5 20 ± 9 25 ± 10 <0.01
Tricuspid regurgitation gradient (mmHg) 20 ± 5 20 ± 5 22 ± 7 26 ± 9 32 ± 15 <0.01
Inferior vena cava diameter (mm) 11 ± 3 10 ± 3 12 ± 5 13 ± 5 19 ± 8 <0.01
Laboratory
AST (U/L) 22 ± 9 21 ± 9 23 ± 8 25 ± 9 35 ± 23 <0.01
ALT (U/L) 21 ± 11 19 ± 10 19 ± 11 20 ± 12 26 ± 16 0.21
ALP (U/L) 226 ± 89 214 ± 82 235 ± 86 243 ± 119 303 ± 83 <0.01
GGT (U/L) 28 ± 31 34 ± 21 30 ± 22 50 ± 52 103 ± 75 <0.01
Total bilirubin (mg/dL) 0.8 ± 0.6 0.6 ± 0.3 0.7 ± 0.3 0.8 ± 0.3 1.4 ± 0.9 <0.01
Cholinesterase (U/L) 310 ± 72 316 ± 94 294 ± 48 271 ± 80 224 ± 80 0.04
Albumin (g/dL) 3.9 ± 0.7 3.9 ± 0.5 4.0 ± 0.5 3.9 ± 0.5 3.6 ± 0.4 0.36
Prothrombin time (s) 10.4 ± 0.6 10.4 ± 0.5 10.6 ± 1.2 11.0 ± 1.4 11.0 ± 0.6 0.16
Haemoglobin (g/dL) 12.6 ± 2.0 12.8 ± 1.1 12.8 ± 1.8 12.7 ± 2.0 11.8 ± 1.6 0.88
Creatinine (mg/dL) 0.7 ± 0.2 0.8 ± 0.2 0.9 ± 0.5 1.1 ± 0.5 1.6 ± 1.5 <0.01
B-type natriuretic peptide (pg/mL) 17 ± 13 30 ± 19 121 ± 137 456 ± 580 762 ± 789 <0.01
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; E/e′, early diastolic mitral inflow velocity to
mitral annular velocity ratio; GGT, γ-glutamyl transpeptidase; LV, left ventricular; RA, right atrial.
Data are presented as mean ± standard deviation or number (%) of patients.
Figure 2 Elasticity and dispersion slope of shear wave according to the American College of Cardiology Foundation/American Heart Association stage
of heart failure. Elasticity was remarkably elevated in Stage D, whereas dispersion slope was gradually increased from Stage A to Stage D. P < 0.01 for
the analysis of variance among five groups.
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Liver function parameters
Liver function test parameters, including AST, ALT, ALP, GGT,
and bilirubin levels, were normal value in patients with Stage
B, whereas an elevation of dispersion slope was observed.
Only GGT level was increased from Stage C. In patients with
Stage D, ALP level was increased, and cholinesterase was de-
creased (Table 1).
Haemodynamic measurements
Cardiac catheterization was performed in 21 patients with
Stage B, 56 with Stage C, and 17 with Stage D (Table 2). Pul-
monary artery wedge pressure, mean pulmonary artery pres-
sure, systolic right ventricular pressure, and RA pressure were
increased from Stage B to Stage D. RA pressure was weakly
correlated with elasticity (r = 0.36, P < 0.01).
Relationships of shear wave elastography with
clinical parameters
Elasticity and dispersion slope were correlated with LV
end-diastolic diameter, LV end-systolic diameter, LV ejection
fraction, LV mass index, left atrial volume index, E/e′, tricus-
pid regurgitation pressure gradient, and RA size. Plasma
B-type natriuretic peptide and serum creatinine levels were
also correlated with elasticity and dispersion slope (Table 3).
Reproducibility
There was good agreement in the measurements of elasticity
between the two blinded observers (r = 0.91, P < 0.01) and
for the intra-observer (r = 0.96, P < 0.01). The
inter-observer and intra-observer variabilities for the value
of elasticity were 6.6% and 5.8%, respectively.
Discussion
The major findings of the present study were as follows: (i)
elasticity of shear wave was remarkably elevated in patients
with Stage D, whereas dispersion slope of shear wave was
gradually increased from Stage A to Stage D; and (ii) an eleva-
tion of dispersion slope was observed prior to the occurrence
of liver function tests abnormalities. SWE, including elasticity
and dispersion slope, can be used to effectively detect liver
damage in the early stage of HF and to assess the progression
of liver dysfunction in patients with HF. To the best of our
knowledge, this is the first study to show the efficacy of
SWE with combined measurement of elasticity and disper-
sion slope in patients with HF.
Liver dysfunction in heart failure
Heart failure causes liver dysfunction, which results in worse
outcomes. Liver function parameters are used to assess three
conditions: cholestasis, which is reflected by ALP, GGT, and
bilirubin; hepatocyte integrity, which is reflected by AST and
ALT; and liver function mass, which is reflected by cholines-
terase, albumin, and prothrombin time levels. Liver function
tests play an important role in the prediction of mortality in
patients with HF,1,2 but abnormalities in the previously men-
tioned parameters are often not observed unless HF is
advanced.22 In the present study, almost liver function pa-
rameters were not changed in Stages A–C. An increase in
Table 2 Haemodynamic measurements
Variables
Stage B Stage C Stage D
P(n = 21) (n = 56) (n = 17)
Pulmonary artery wedge pressure (mmHg) 11 ± 4 12 ± 7 21 ± 7 <0.01
Mean pulmonary artery pressure (mmHg) 17 ± 4 20 ± 9 28 ± 10 <0.01
Systolic right ventricular pressure (mmHg) 27 ± 7 31 ± 12 45 ± 14 <0.01
Right atrial pressure (mmHg) 4 ± 3 6 ± 5 9 ± 5 <0.01
Cardiac output (L/min) 3.7 ± 1.5 3.6 ± 1.5 3.2 ± 0.8 0.58
Cardiac index (L/min/m2) 2.4 ± 0.8 2.3 ± 0.8 2.0 ± 0.4 0.35
Data are presented as mean ± standard deviation.




r P value r P value
Echocardiography
LV end-diastolic diameter 0.19 <0.01 0.16 <0.01
LV end-systolic diameter 0.20 <0.01 0.19 <0.01
LV ejection fraction 0.22 <0.01 0.24 <0.01
LV mass index 0.25 <0.01 0.27 <0.01
Left atrial volume index 0.55 <0.01 0.36 <0.01
RA size 0.45 <0.01 0.44 <0.01
E/e′ 0.22 <0.01 0.32 <0.01
Tricuspid regurgitation
pressure gradient
0.22 <0.01 0.25 <0.01
Laboratory
Creatinine 0.04 0.04 0.16 <0.01
B-type natriuretic peptide 0.23 <0.01 0.22 <0.01
E/e′, early diastolic mitral inflow velocity to mitral annular velocity
ratio; LV, left ventricular; RA, right atrial.
Efficacy of shear wave elastography in patients with HF 5
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13318
bilirubin level and a decrease in cholinesterase level were ob-
served in Stage D. In the liver, 70% of the blood supply is de-
pendent on the portal system, and 30% is delivered by the
hepatic artery. Because blood is supplied from both systems,
liver function test abnormalities are less likely to occur.19
Evaluation of liver damage using liver function parameters
is difficult in the early stage of HF. Few methods are available
to effectively diagnose early liver damage in patients with HF.
Shear wave elastography
Shear wave elastography provides information regarding
elasticity of shear wave, which is calculated by shear wave
speed, as well as dispersion slope of shear wave, which re-
flects the frequency dependence of both speed and attenua-
tion of shear waves in the viscous component.11,12,21 SWE has
been recognized as a useful method for assessing liver
diseases.13–16,23,24 Elasticity is significantly increased in
cirrhosis.13,14 Dispersion slope is more sensitively increased
in hepatitis and fatty liver.15,16 In the field of heart disease,
several studies have reported that elasticity is correlated with
central venous pressure in acute phase of HF, which is asso-
ciated with cardiac events.25–28 However, the usefulness of
SWE has not been fully investigated in patients with HF. Ad-
ditionally, because these studies have focused on only elastic-
ity, the assessments of the clinical significance of dispersion
slope are lacking.
The present study investigated the efficacy of both elas-
ticity and dispersion slope in patients with different sever-
ities of HF, including patients without HF and
asymptomatic patients with HF. Thus, this study was able
to clarify the graduated changes in elasticity and dispersion
slope according to the stage of HF. Dispersion slope was el-
evated in the early stage of HF, such as Stage B. In the ad-
vanced stage of HF, such as Stage D, both elasticity and
dispersion slope were increased with the remarkable eleva-
tion of elasticity. Interestingly, dispersion slope was elevated
prior to the appearance of liver function test abnormalities.
When liver function test abnormalities occurred, both elas-
ticity and dispersion slope were already increased. In pa-
tients with HF, venous congestion initially leads to
compress bile canaliculi and ductules in the liver. The persis-
tence of this state causes necrosis of liver cells due to
hypoperfusion,19 resulting in liver function test abnormali-
ties. Dispersion slope may be able to detect the initial state
of venous congestion in the liver. Therefore, SWE has a po-
tential to diagnose liver damage more sensitively than liver
function test. Based on these findings, the present study
suggests that dispersion slope can be used to effectively de-
tect early liver damage and that the combination of elastic-
ity and dispersion slope distinguishes the degree of liver
damage in patients with HF. In the present study, the sensi-
tivity and specificity of SWE for identifying the stage of HF
were not high. However, we consider that SWE is useful to
estimate the severity of HF, including the other clinical
parameters.
Previous studies have reported that elasticity is strongly
correlated with central venous pressure in patients with
acute decompensated HF.25–27 The liver is enveloped by a
non-elastic capsule. Increased central venous pressure
causes an enlarged and firm liver. Because elasticity reflects
the tissue hardness, high value of elasticity is reasonable in
the acute phase of HF. In the present study, elasticity was
correlated with RA pressure, but the correlation was weak.
As the reason, we consider that elasticity was measured at
the time of outpatient clinic or at discharge from HF treat-
ment, which was the chronic phase of HF. Elasticity is reflec-
tive of central venous pressure and HF-induced liver
fibrosis.29–31 In the chronic phase of HF, elasticity may be
more strongly affected by liver fibrosis complicated by
long-standing HF.
Clinical implications
Because liver dysfunction is a prognostic factor in patients
with HF, it is important to diagnose early liver damage and
the degree of liver dysfunction in clinical practice. SWE is a
simple, objective, and non-invasive modality to assess liver
function. The present study suggests that SWE can evaluate
liver dysfunction from early stage to advanced stage of HF.
Furthermore, SWE can become a novel technique with which
to differentiate the stage of HF. Especially, dispersion slope
may be effective for identifying Stage B. Because transition
from Stage B to Stage C portends an increase in mortality
risk,32 the determination of Stage B is important for the pre-
vention of HF.33 In the clinical setting, SWE can provide infor-
mation for the progression of HF and may be effective for
establishing therapeutic strategies of HF. Furthermore, SWE
may be useful to judge the effects of HF therapies.
Study limitations
There are several limitations in the present study. First, the
number of patients was relatively small for assessment of
the usefulness of SWE in patients with HF. The number of pa-
tients with each stage of HF was different. Larger studies are
required to confirm our findings. Second, cardiac catheteriza-
tion was not performed in all patients. Third, this study ex-
cluded patients with liver disease, but this might have been
insufficient. Liver biopsy was not performed for ethical rea-
sons. SWE measurements might be affected by liver disease.
Finally, the relationships between SWE parameters and histo-
logical findings were not assessed.
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Conclusions
Elasticity of shear wave was remarkably elevated in Stage D,
whereas dispersion slope of shear wave was gradually in-
creased from Stage A to Stage D. An elevation of dispersion
slope occurred prior to the appearance of liver function tests
abnormalities. Assessment of dispersion slope may be able to
detect early liver damage in patients with HF. The combina-
tion of elasticity and dispersion slope has the potential to
clarify the progression of liver dysfunction. SWE may be valu-
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